Iron oxide nanoparticulate system as a cornerstone in the effective delivery of Tc-99m radionuclide: a potential molecular imaging probe for tumor diagnosis
Swidan M.M.; Khowessah O.M.; El-Motaleb M.A.; El-Bary A.A.; El-Kolaly M.T.; Sakr T.M.
Date issued:
2019
Publisher:
Springer
Series Info:
DARU, Journal of Pharmaceutical Sciences
27
Type:
Article
Keywords:
October University for Modern Sciences and Arts
,
جامعة أكتوبر للعلوم الحديثة والآداب
,
University of Modern Sciences and Arts
,
MSA University
,
Chelator free radiolabeling
,
Encapsulation
,
Magnetic iron oxide nanoparticles
,
Tc-99m radionuclide
,
Tumor delivery
,
Tumor diagnosis
,
magnetic iron oxide nanoparticle
,
magnetic nanoparticle
,
technetium 99m
,
ultrasmall superparamagnetic iron oxide
,
unclassified drug
,
ferric ion
,
ferric oxide
,
magnetite nanoparticle
,
technetium
,
Technetium-99
,
animal experiment
,
animal model
,
animal tissue
,
Article
,
cell viability
,
chemical parameters
,
controlled study
,
drug cytotoxicity
,
drug delivery system
,
drug stability
,
encapsulation efficiency
,
human
,
human cell
,
hydrodynamic size
,
in vitro study
,
in vivo study
,
isotope labeling
,
molecular imaging
,
mouse
,
nanoencapsulation
,
nonhuman
,
particle charge
,
particle size
,
physical parameters
,
radiochemical purity
,
synthesis
,
tumor diagnosis
,
ultrasound
,
zeta potential
,
animal
,
cancer transplantation
,
cell line
,
cell survival
,
chemistry
,
diagnostic imaging
,
intravenous drug administration
,
Administration, Intravenous
,
Animals
,
Cell Line
,
Cell Survival
,
Ferric Compounds
,
Humans
,
Magnetite Nanoparticles
,
Mice
,
Neoplasm Transplantation
,
Particle Size
,
Technetium
Abstract:
Background: The evolution of nanoparticles has gained prominence as platforms for developing diagnostic and/or therapeutic radiotracers. This study aims to develop a novel technique for fabricating a tumor diagnostic probe based on iron oxide nanoparticles excluding the utilization of chelating ligands. Methods: Tc-99m radionuclide was loaded into magnetic iron oxide nanoparticles platform (MIONPs) by sonication. 99mTc-encapsulated MIONPs were fully characterized concerning particles size, charge, radiochemical purity, encapsulation efficiency, in-vitro stability and cytotoxicity. These merits were biologically evaluated in normal and solid tumor bearing mice via different delivery approaches. Results: 99mTc-encapsulated MIONPs probe was synthesized with average particle size 24.08 7.9nm, hydrodynamic size 52nm, zeta potential -28mV, radiolabeling yield 96 0.83%, high in-vitro physiological stability, and appropriate cytotoxicity behavior. The in-vivo evaluation in solid tumor bearing mice revealed that the maximum tumor radioactivity accumulation (25.39 0.57, 36.40 0.59 and 72.61 0.82%ID/g) was accomplished at 60, 60 and 30min p.i. for intravenous, intravenous with physical magnet targeting and intratumoral delivery, respectively. The optimum T/NT ratios of 57.70, 65.00 and 87.48 were demonstrated at 60min post I.V., I.V. with physical magnet targeting and I.T. delivery, respectively. These chemical and biological characteristics of our prepared nano-probe demonstrate highly advanced merits over the previously reported chelator mediated radiolabeled nano-formulations which reported maximum tumor uptakes in the scope of 3.65 0.19 to 16.21 2.56%ID/g. Conclusion: Stabilized encapsulation of 99mTc radionuclide into MIONPs elucidates a novel strategy for developing an advanced nano-sized radiopharmaceutical for tumor diagnosis. [Figure not available: see fulltext.]. 2019, Springer Nature Switzerland AG.
Description:
Scopus
MSA Google Scholar
Show full item record